About Veronica Donato
I am a Scientist with a PhD in Biological Sciences who focused her last years of research exploring the relationship between bacteria and their host with the goal to contribute with basic results that could help to cure/ treat some diseases and mitigate the aging process. I am also been actively involved in teaching and mentoring students because I really think that cooperate in the development of new skills and knowledge is extremely important in the advance of Science and in the empowerment of the minority population in this field. For this, I joined Northeastern University as a lecturer.
After these basic research valuable experiences, following my aspiration to translate my findings to clinic and to reach community in a more direct way, I decided to start a new pathway in my career. I joined a Training Program in Clinical and Translational Research at Harvard Medical School as the beginning of this new track. After completing this training, I applied for the Clinical Investigation Master Program at Harvard Medical School (where I was accepted to start July 2020) and joined Dana-Farber Cancer Institute in the Medical Oncology Department as a part-time Research Fellow to conducting translational research focused on the post-transplant immune reconstitution and chronic graft-versus-host-disease in pediatric patients.
I chose this field in Clinical/Translational Research because my interests are focused on hematopoietic stem cell transplantation (HSCT) in children. Children patients suffering malignant and non-malignant diseases interested me because I think they are a vulnerable population and any advance in helping them to recover or mitigate their diseases is an advance in improving their quality of life and the medical system.
My professional goals are focused on the optimization of the immune reconstitution after HSCT. These coming years allows me to apply my scientific training in a translational/clinical set to discover or develop new approaches for the prevention and treatment of adverse effects of HSCT in children.
I feel fortunate to have the opportunity to apply the knowledge and skills from my laboratory training to answer questions with important clinical implications in HSCT and learning new techniques and clinical concepts.
With the support of my Master mentors, my Dana-Farber mentor and senior faculty in my division I envision a career where I can reach new discoveries and bring new therapies to the clinic.
As a first step in this new pathway, I will start the Master Program. The Master Program in Clinical Investigation will grant me a period of formal mentored career development to advance my translational research in the pediatric HSCT field, and to facilitate my transition to an independent translational/clinical research-scientist position in a competitive academic or industry setting. Moreover, to stay up to date with the most current research and to increase my visibility in the HSCT field, I will attend and present my work at national and international conferences and I will attend formal training to gain more expertise in this new field.
My long-term goal is to be a Lead Interdisciplinary Scientist and a member of a Scientist/clinical Board guiding and giving advices in the development of different projects in the translational/clinical set.
Teaching is also my passion and mentoring students is a priority in my career.